{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.7643.2.1006","meta":{"versionId":"6","lastUpdated":"2019-01-08T01:00:08.000-05:00"},"text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">\n      <h2>Checkpoint Inhibitors with Potential to Cause Grade 3 or Higher Fatigue</h2>\n      <p>This value set includes codes from the following code systems:</p>\n      <ul>\n        <li>Include these codes as defined in \n          <a href=\"http://www.nlm.nih.gov/research/umls/rxnorm\">\n            <code>http://www.nlm.nih.gov/research/umls/rxnorm</code>\n          </a>\n          <table class=\"none\">\n            <tr>\n              <td>\n                <b>Code</b>\n              </td>\n              <td>\n                <b>Display</b>\n              </td>\n            </tr>\n            <tr>\n              <td>1657005</td>\n              <td>40 ML ipilimumab 5 MG/ML Injection</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>1657012</td>\n              <td>10 ML ipilimumab 5 MG/ML Injection</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>1657190</td>\n              <td>4 ML nivolumab 10 MG/ML Injection</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>1657195</td>\n              <td>10 ML nivolumab 10 MG/ML Injection</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>1657746</td>\n              <td>pembrolizumab 50 MG Injection</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>1657750</td>\n              <td>4 ML pembrolizumab 25 MG/ML Injection</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>1792780</td>\n              <td>20 ML atezolizumab 60 MG/ML Injection</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>1875542</td>\n              <td>10 ML avelumab 20 MG/ML Injection</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>1919507</td>\n              <td>2.4 ML durvalumab 50 MG/ML Injection</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>1919515</td>\n              <td>10 ML durvalumab 50 MG/ML Injection</td>\n              <td/>\n            </tr>\n            <tr>\n              <td>1991412</td>\n              <td>24 ML nivolumab 10 MG/ML Injection</td>\n              <td/>\n            </tr>\n          </table>\n        </li>\n      </ul>\n    </div>"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.7643.2.1006","version":"20190108","name":"Checkpoint Inhibitors with Potential to Cause Grade 3 or Higher Fatigue","status":"active","date":"2019-01-08T01:00:08-05:00","publisher":"Oncology Nursing Society Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","concept":[{"code":"1657005","display":"40 ML ipilimumab 5 MG/ML Injection"},{"code":"1657012","display":"10 ML ipilimumab 5 MG/ML Injection"},{"code":"1657190","display":"4 ML nivolumab 10 MG/ML Injection"},{"code":"1657195","display":"10 ML nivolumab 10 MG/ML Injection"},{"code":"1657746","display":"pembrolizumab 50 MG Injection"},{"code":"1657750","display":"4 ML pembrolizumab 25 MG/ML Injection"},{"code":"1792780","display":"20 ML atezolizumab 60 MG/ML Injection"},{"code":"1875542","display":"10 ML avelumab 20 MG/ML Injection"},{"code":"1919507","display":"2.4 ML durvalumab 50 MG/ML Injection"},{"code":"1919515","display":"10 ML durvalumab 50 MG/ML Injection"},{"code":"1991412","display":"24 ML nivolumab 10 MG/ML Injection"}]}]}}